The role of ibrutinib in COVID-19 hyperinflammation: a case report
File(s)1-s2.0-S1201971221001429-main.pdf (354.22 KB)
Published version
Author(s)
Type
Journal Article
Abstract
Continuing ibrutinib in patients with COVID-19 may be advantageous given its immunomodulatory properties and withdrawal of ibrutinib therapy may be detrimental. Further evidence is required to explore the potential therapeutic impact of BTKis and other immunomodulatory agents on the clinical course of COVID-19 as is currently being carried out in a number of clinical trials.
Date Issued
2021-04
Date Acceptance
2021-02-11
Citation
International Journal of Infectious Diseases, 2021, 105, pp.274-276
ISSN
1201-9712
Publisher
Elsevier
Start Page
274
End Page
276
Journal / Book Title
International Journal of Infectious Diseases
Volume
105
Copyright Statement
Crown Copyright © 2021 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-NDlicense (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Identifier
https://www.sciencedirect.com/science/article/pii/S1201971221001429?via%3Dihub
Subjects
BTK-inhibitor
COVID-19
Ibrutinib
Waldenstrom macroglobulinaemia
Microbiology
0605 Microbiology
1108 Medical Microbiology
1117 Public Health and Health Services
Publication Status
Published
Date Publish Online
2021-02-16